Paul Lawrence

Executive Director of Bioscience Research Biocogent

Dr. Lawrence received his doctorate in molecular microbiology from Stony Brook University and before that obtained his Bachelor of Science degree in molecular biology from the University of New Mexico. During his career, he has conducted biological research in academia, industry, and for the United States government. He has executed anti-viral therapeutic and vaccine research projects at Brookhaven National Laboratory and the Plum Island Animal Disease Center. In industry, he has participated in contract biopharmaceutical projects for the former Collaborative Bioalliance as well as Dow Chemical. Dr. Lawrence was also the Director of DNA Production for the anti-counterfeiting biotechnology company, Applied DNA Sciences. Currently, he is the Executive Director of Bioscience Research, Discovery, and Scientific Communications for Biocogent, a developer and manufacturer of bio-active ingredients with cosmetic care applications. In his spare time, he is also an adjunct professor at three different colleges teaching microbiology to future nurses and doctors. He also volunteers as an associate technical editor for the Journal of Cosmetic Science and is currently the Chair of the Committee on Scientific Affairs for the Society of Cosmetic Chemists. He has also been an instructor for several courses with the SCC’s continuing education program. Over the course of his career, Dr. Lawrence has published more than 30 research manuscripts and review articles, more than 25 online science digests, and has authored a textbook chapter on the molecular pathogenesis of one of the world’s most infectious viruses.

Seminars

Thursday 28th January 2027
Fireside Chat: Defining the Next Frontier of RNAi Therapeutics to Target Beyond the Liver
9:00 am
  • Examining why extrahepatic delivery is the field’s defining challenge
  • Focusing investment and research on the right bottlenecks
  • Defining the milestones that will signal the arrival of truly routine extrahepatic RNAi delivery
Thursday 28th January 2027
Adapting Modern MicroRNA Technology to Improve Skin Health
1:00 pm
  • Identifying and developing miRNA-based active ingredients for topical delivery
  • Surmounting the obstacles presented by the antagonistic relationship between RNA molecules and human skin
  • Designing a delivery vehicle for miRNA-based actives that both protects and effectively delivers the RNA payload to viable cells
Paul Lawrence